iMedica s.r.o.
- Address
- Sosnova 757/2b, Jundrov, 637 00 Brno, Czechia
iMedica s.r.o. - Autoimmune Disease Research Center
iMedica s.r.o. is a specialized clinical research facility focused on advancing treatments for complex autoimmune disorders. The center demonstrates particular expertise in conducting both pivotal efficacy trials and long-term safety studies for novel therapeutic agents in systemic lupus erythematosus (SLE), contributing to the development of innovative immunomodulatory therapies.
- Systemic lupus erythematosus (SLE) treatment development and disease activity assessment
- Long-term safety and tolerability evaluation of immunomodulatory agents
- Novel sphingosine-1-phosphate receptor modulators in autoimmune conditions
The research center's portfolio includes comprehensive investigation of cenerimod, focusing on both short-term efficacy outcomes and extended safety profiles in patients with moderate to severe SLE. Their dual approach encompasses both controlled efficacy evaluations and open-label extension studies, ensuring thorough assessment of therapeutic interventions across the full spectrum of clinical development in autoimmune disease management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Viatris Innovation GmbH1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Viatris Innovation GmbH2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in iMedica s.r.o.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Cenerimod Efficacy and Safety in Adults with Moderate-to-Severe Systemic Lupus Erythematosus: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study | Viatris Innovation GmbH | Phase III | Not Recruiting | Oct 2024 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cenerimod | 2 | Unknown | 2024-10-24 | 2024-11-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.